Archive for the ‘Regenicin, Inc. RGIN’ Category

Regenicin, Inc. (RGIN) Repays Loans; Continues to Execute Business Strategy

Friday, June 17th, 2011

Regenicin, Inc., a biotechnology company focused on developing regenerative cell therapies to restore the health of damaged tissues and organs, today announced the repayment of short-term secured loans totaling $242,993.54.

The company received these short-term loans from supporters of the company, including members of its board of directors, to finance operations. The repayment fully satisfied the terms of the loans, thereby releasing the company’s assets that were held as security.

The three board members who were reimbursed for their loan contributions were Dr. Craig Eagle, John Weber and Dr. Joseph Rubinfeld.

“The short-term loans extended to us were from people who genuinely want us to succeed in bringing new product candidates to market in the field of regenerative medicine,” stated Randall McCoy, CEO of Regenicin. “We are pleased to have the financial wherewithal to repay these valuable contributors and continue on our path to fulfill our business objectives.”

Let us hear your thoughts: Regenicin, Inc. Message Board

Regenicin, Inc. (RGIN) Management Team Focused on Tissue-Engineered Skin Technology

Wednesday, June 15th, 2011

There’s no question that some of the biggest moves in advanced healthcare technology today involve the use of a patient’s own cells, from attacking various diseases to the rebuilding of aged or damaged tissues. In the case of Regenicin, Inc., a New Jersey based biotechnology company, it’s all about the development of regenerative cell therapies to restore the health of damaged tissues. The company is currently working on a breakthrough technology that uses a patient’s own skin cells to generate living tissue-engineered skin for the treatment of burns and wounds. It represents a huge step for the thousands of severe burn cases occurring every year, promising less scaring, fewer infections, and faster healing.

Heading the effort is the Regenicin management team, each with an expertise in a particular aspect of the medical field.

• Randall McCoy (Chairman, CEO) has 37 years of healthcare industry experience, at both the scientific and executive levels, and has assisted small and large pharmaceutical and device companies in the addressing of FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products to the U.S. and world markets, and himself holds over 30 U.S. and international patents. His previous employment includes George Washington University, Temple University Medical School, and RCA/SRI International (Director of Life Sciences and Electronic Displays).

• John Weber (Interim CFO) served many years with Fujifilm Medical Systems USA, rising to Executive Vice President, the highest ranked American corporate officer, until his departure in 2009. During his time with the company, he spearheaded its transition from a film distributor to a digital medical informatics company, helping profitably manage the company’s growth from an employee base of only 75 to well over 1,000. Prior to this, he served as CFO and Corporate Controller for a division of Cadbury Schweppes.

• Chris Hadsall (COO), a 10-year veteran of the U.S. Marine Corps, brings experience as founder and Executive Director of the VET Foundation, dedicated to helping injured veterans transition to civilian life. He designed, developed, and implemented a holistic reintegration program, in addition to being responsible for fund raising and the financial health of the organization. Prior to that, he worked as Regional Manager for Professional Staffing ABTS, guiding day-to-day operations and business development for a major expansion.

• Richard Koeninger (Director of Regulatory Affairs) offers 29 years of experience with the FDA, where he worked in Field Investigations and as a Drug and Device Specialist, and overseas as the Associate Director of Emergency and Investigational Operations, and had the distinction of being the International FDA Expert for Drugs and Devices. He has served on Institutional Review Boards for clinical trials, and has conducted FDA pre-approval investigations.

• Lauri-Ann Hahn (Director of Clinical Trials) is experienced in all areas of clinical research, from planning and conducting studies, to FDA clinical report submissions. She served as Associate Director of Clinical Trials and Sr. Project Manager for Lonza Walkersville, Inc., where she gained direct experience working with Cultured Skin Substitute. She has also worked at the National Institutes of Health, and was Head of Clinical Research at the University of Pittsburgh Department of Urology.

For additional information, visit the company’s website at www.Regenicin.com

Let us hear your thoughts: Regenicin, Inc. Message Board

Regenicin, Inc. (RGIN) Reports Dismissal of Lawsuit

Thursday, June 9th, 2011

Earlier this morning, Regenicin, Inc. announced it reached an agreement with former company president Mr. Joseph Connell. The parties agreed to dismiss the company and the board of directors which were named in the lawsuit pending in the US District Court for the Southern District of New York. The company in turn has dismissed its action against Mr. Connell.

In the press release, the company noted there will be a continued action pending by and between Mr. Connell and Mr. McCoy, the current CEO, but that this dispute is anticipated to be settled. The parties recognize this was a partnership dispute and agreed that Regenicin, its board and shareholders should not be affected by this matter.

Mr. McCoy commented, “Mr. Connell and I had a previous business partnership separate and away from Regenicin. This matter is and has always been between the individual parties so I’m very pleased to have the matter formally resolved for our company and the board.”

Let us hear your thoughts: Regenicin, Inc. Message Board

Regenicin, Inc. (RGIN) in Advanced Discussions with Developers to Establish New Facilities in Florida

Wednesday, June 8th, 2011

Today shortly before the closing bell, Regenicin, Inc. announces it is in advanced discussions with various developers in the State of Florida to determine the most strategic location and best partners to establish research facilities. Sites presently being considered are world-class research and technology parks, which will allow Regenicin to collaborate with leading centers of excellence in the academic, research, and healthcare arenas.

Regenicin is pursuing opportunities to lease new facilities that will not only accommodate the present demands for state-of-the-art lab space, but will also address the projected growth needs the company foresees as it executes its business plan.

Regenicin believes the state of Florida is not only an exciting new destination, but will also offer many appealing amenities with logistical and financial considerations for the biotech and life sciences industries. The company hopes to announce its site selection in the near future.

Let us hear your thoughts: Regenicin, Inc. Message Board

Regenicin, Inc. (RGIN) Director Attends the World Stem Cells and Regenerative Medicine Congress 2011

Tuesday, June 7th, 2011

Regenicin, Inc. just announced that Dr. Craig Eagle, who sits on the Regenicin Board of Directors, attended The World Stem Cells and Regenerative Medicine Congress 2011 in an effort to further Regencin’s push towards obtaining FDA approval for the commercial sale of its first product candidate.

The World Stem Cells and Regenerative Medicine Congress is recognized for offering a senior director-level, interactive conference experience. Speakers and panelists include industry leaders from throughout Europe, North America and Asia. The World Stem Cells and Regenerative Medicine Congress is Europe’s most progressive strategic conference where ideas, intelligence and relationships really make a difference.

“The World Stem Cells and Regenerative Medicine Congress plays a vital role in advancing awareness of the most ground-breaking developments in the field, recognizing key industry leaders, and facilitating top level conversations about strategic planning and partnerships,” stated Randall McCoy, CEO of Regenicin. “It is great to see that Regenicin is perfectly in line with stem cell technology that is being pursued by the rest of the world.”

Regenicin, Inc. is a biotechnology company with corporate headquarters in Little Falls, New Jersey. The Company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. With a solid business model in place, Regenicin is positioning itself to become a leader in one of the fastest growing industries in biotechnology.

Let us hear your thoughts: Regenicin, Inc. Message Board

Regenicin, Inc. (RGIN) is “One to Watch”

Monday, June 6th, 2011

Regenicin, Inc., headquartered in Little Falls, New Jersey, is a biotechnology company focused on developing regenerative cell therapies to restore the health of damaged tissues and organs. The company has assembled a world-class management team with a proven track record of developing and bringing innovative medical devices and biotechnology products to market.

The company is playing a critical role in the development of the therapeutic candidate, PermaDerm™, a breakthrough technology that uses a patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns and wounds. Using only a postage-stamp biopsy of the patient’s skin, a sheet of PermaDerm™ 100 times the initial size can be grown in as little as 30 days.

PermaDerm™ is being developed to be the only tissue-engineered skin prepared from autologous skin cells consisting of both epidermal and dermal layers. The technology has been clinically tested in more than 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.

The tissue engineering and cell therapy market is anticipated to grow from $6.9 billion in 2009 to almost $32 billion by 2018 in the U.S. alone, according to MedMarket Diligence. This rapid growth has been primarily attributed to proven clinical benefits, a clearly defined regulatory path, and clinicians’ readiness to adopt these new therapies. With a solid business model in place, Regenicin is positioning itself to become a leader in one of the fastest growing industries in biotechnology.

Let us hear your thoughts: Regenicin, Inc. Message Board